未來股份(600532.SH):智谷一期已完成工商登記手續
格隆匯6月2日丨未來股份(600532.SH)公吿,公司於2021年5月12日與濟南高新財金投資有限公司(“高新財金”)、上海佳杭醫院管理有限公司(“上海佳杭”)簽署了《合夥協議》,共同出資設立未來智谷一期(濟南)醫療投資管理合夥企業(有限合夥)(“智谷一期”),公司作為有限合夥人以自有資金出資人民幣1.35億元投資合夥企業,智谷一期以自有資金對外投資設立濟南高新未來國際醫院有限公司(“未來國際醫院”)。
近日,公司獲悉智谷一期已完成了工商註冊登記手續,並取得了濟南高新技術產業開發區管委會頒發的《營業執照》。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.